Published in Stem Cell Week, June 28th, 2004
Under the terms of the agreement, company researchers will apply Athersys' two proprietary technologies, the RAGE (Random Activation of Gene Expression) platform and MAPC (Multipotent Adult Progenitor Cell) technology - a novel adult-derived stem cell originally discovered by Catherine Verfaillie and her colleagues at the University of Minnesota.
Research conducted by Verfaillie and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.